TOP NEWS

October 29, 2026
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
October 26, 2026
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
October 08, 2026
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
VIEW ALL

WE ARE SOCIAL